Literature DB >> 26183926

Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.

Marco Donia1, Rikke Andersen2, Julie W Kjeldsen3, Paolo Fagone4, Shamaila Munir3, Ferdinando Nicoletti4, Mads Hald Andersen3, Per Thor Straten3, Inge Marie Svane5.   

Abstract

In the absence of a local inflammatory response, expression of MHC class II molecules is restricted mainly to hematopoietic cells and thymus epithelium. However, certain tumors, such as melanoma, may acquire aberrant constitutive expression of MHC class II. In a set of primary melanoma cell populations and correspondingly expanded autologous tumor-infiltrating lymphocytes (TIL), we show how MHC class II expression on melanoma cells associates with strong MHC class II-restricted CD4(+) T-cell responses that are specific for tumors. Notably, we found that tumor-specific CD4(+) T-cell responses were dominated by TNF production. TNF reduced CD8(+) T-cell activation in IFNγ-rich environments resembling a tumor site. Conversely, direct CD4(+) T-cell responses had no influence on either the proliferation or viability of melanoma cells. Taken together, our results illustrate a novel immune escape mechanism that can be activated by aberrant expression of MHC class II molecules, which by attracting tumor-specific CD4(+) T cells elicit a local inflammatory response dominated by TNF that, in turn, inhibits cytotoxic CD8(+) T-cell responses ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26183926     DOI: 10.1158/0008-5472.CAN-14-2956

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.

Authors:  Ailing Wu; Qingzhe Wu; Yujie Deng; Yuning Liu; Jinqiu Lu; Liansheng Liu; Xiaoling Li; Cheng Liao; Bin Zhao; Hai Song
Journal:  EMBO J       Date:  2018-11-05       Impact factor: 11.598

Review 2.  The opposing roles of CD4+ T cells in anti-tumour immunity.

Authors:  Tomasz Ahrends; Jannie Borst
Journal:  Immunology       Date:  2018-04-27       Impact factor: 7.397

Review 3.  Cutaneous squamous cell cancer (cSCC) risk and the human leukocyte antigen (HLA) system.

Authors:  Pooja Yesantharao; Wei Wang; Nilah M Ioannidis; Shadmehr Demehri; Alice S Whittemore; Maryam M Asgari
Journal:  Hum Immunol       Date:  2017-02-07       Impact factor: 2.850

4.  The controversial role of TNF in melanoma.

Authors:  Marco Donia; Julie Westerlin Kjeldsen; Inge Marie Svane
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

5.  Detection of ABCB5 tumour antigen-specific CD8+ T cells in melanoma patients and implications for immunotherapy.

Authors:  S Borchers; C Maβlo; C A Müller; A Tahedl; J Volkind; Y Nowak; V Umansky; J Esterlechner; M H Frank; C Ganss; M A Kluth; J Utikal
Journal:  Clin Exp Immunol       Date:  2017-10-24       Impact factor: 4.330

6.  CD4+ T cell-mediated cytotoxicity eliminates primary tumor cells in metastatic melanoma through high MHC class II expression and can be enhanced by inhibitory receptor blockade.

Authors:  Hongxia Yan; Xianglian Hou; Tianhang Li; Li Zhao; Xiaozhou Yuan; Hongjun Fu; Ruijie Zhu
Journal:  Tumour Biol       Date:  2016-10-05

Review 7.  Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.

Authors:  Elisa Ruffo; Richard C Wu; Tullia C Bruno; Creg J Workman; Dario A A Vignali
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

Review 8.  LAG3 (CD223) as a cancer immunotherapy target.

Authors:  Lawrence P Andrews; Ariel E Marciscano; Charles G Drake; Dario A A Vignali
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 9.  Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

Authors:  Elizabeth H Byrne; David E Fisher
Journal:  Cancer       Date:  2017-06-01       Impact factor: 6.860

10.  Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes.

Authors:  Amalie Kai Bentzen; Andrea Marion Marquard; Rikke Lyngaa; Sunil Kumar Saini; Sofie Ramskov; Marco Donia; Lina Such; Andrew J S Furness; Nicholas McGranahan; Rachel Rosenthal; Per Thor Straten; Zoltan Szallasi; Inge Marie Svane; Charles Swanton; Sergio A Quezada; Søren Nyboe Jakobsen; Aron Charles Eklund; Sine Reker Hadrup
Journal:  Nat Biotechnol       Date:  2016-08-29       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.